DMT1 (Divalent Metal Transporter 1), also known as SLC11A2 (Solute Carrier Family 11 Member 2), is a transmembrane iron transporter essential for cellular iron uptake. It is encoded by the SLC11A2 gene located on chromosome 12q14.2 and functions as a proton-coupled metal ion transporter that imports ferrous iron (Fe²⁺) and other divalent metals into cells. DMT1 is expressed in multiple tissues, including the duodenum (where it absorbs dietary iron), brain, liver, and kidneys. The protein plays a critical role in systemic iron homeostasis and has been implicated in neurodegenerative diseases, particularly Parkinson's disease, where iron accumulation in the substantia nigra is a hallmark feature. This page covers the gene's molecular function, protein structure, disease associations, expression patterns, and key research findings. [1][2]
| Property | Value |
|---|---|
| Gene Symbol | DMT1 (SLC11A2) |
| Alternative Names | DCT1, NRAMP2, Divalent Cation Transporter 1 |
| Chromosomal Location | 12q14.2 |
| Ensembl ID | ENSG00000104691 |
| NCBI Gene ID | 6554 |
| OMIM | 604187, 600042 |
| UniProt ID | Q8IWU6 |
| Protein Length | 495 amino acids |
| Molecular Weight | ~54 kDa |
DMT1 is a member of the NRAMP (Natural Resistance-Associated Macrophage Protein) family and contains several structural features:
DMT1 contains 12 transmembrane helices that form the transport channel. The protein adopts a pseudo-symmetric fold typical of the NRAMP family, with two similar halves forming a central pore. The transmembrane domains are arranged to create a pathway for ion movement across the membrane.
The interior of the transporter contains conserved residues that coordinate metal ion binding. Key binding sites include:
The N-terminal and C-terminal cytosolic domains contain regulatory motifs that control transporter activity through:
DMT1 contains a GATE (GABA Transporter) domain and proline-rich regions that may participate in protein interactions and trafficking regulation.
DMT1 functions as a proton-coupled divalent metal transporter:
DMT1 transports multiple divalent metals:
DMT1 activity is regulated at multiple levels:
DMT1 exhibits broad tissue distribution with highest expression in absorptive and metabolic tissues:
| Tissue/Cell Type | Expression Level |
|---|---|
| Duodenum (enterocytes) | Very High |
| Brain (neurons, glia) | High |
| Kidney (proximal tubule) | High |
| Liver | Moderate |
| Spleen | Moderate |
| Lung | Moderate |
| Heart | Low-Moderate |
| Skeletal Muscle | Low |
In the brain, DMT1 is expressed in:
DMT1 has emerged as a significant player in Parkinson's disease pathogenesis:
Iron Accumulation: DMT1-mediated iron uptake contributes to iron accumulation in the substantia nigra of PD patients. This iron accumulation leads to oxidative stress through Fenton chemistry, generating reactive oxygen species (ROS) that damage dopaminergic neurons.
DMT1 Overexpression: Studies show increased DMT1 expression in PD brains, particularly in the substantia nigra. This overexpression may be driven by iron dysregulation and create a feed-forward loop of iron accumulation.
Genetic Variants: Certain SLC11A2 polymorphisms have been associated with PD risk. Some variants may lead to increased transporter activity or altered regulation.
Neurotoxicity: Iron overload via DMT1 can:
Therapeutic Implications: DMT1 inhibitors are being explored as potential neuroprotective agents in PD. Iron chelation therapy has shown some promise in clinical trials.
DMT1 contributes to AD pathogenesis through several mechanisms:
Brain Iron Dysregulation: Like PD, AD features iron accumulation in affected brain regions. DMT1 may contribute to this dysregulation.
Amyloid Precursor Protein (APP) Processing: Iron affects APP expression and processing. DMT1-mediated iron uptake may influence amyloid-beta production.
Oxidative Stress: Iron-catalyzed oxidative damage is a feature of AD pathology.
While primarily associated with other genes (e.g., PANK2), DMT1 variants can contribute to iron accumulation phenotypes:
DMT1 loss-of-function leads to impaired intestinal iron absorption:
DMT1 expression is altered in certain cancers:
Mus musculus: Multiple mouse models have been generated:
Danio rerio (Zebrafish): Used to study DMT1 function in development and iron transport.
DMT1 is clinically relevant in several contexts: